Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5718982 | 0.92 | HTR2A (0.42) | HTR2AL3MBTL1MAOBSMN1; SMN2MAPT | |
| SCHEMBL5719240 | 0.90 | HTR2A (0.40) | HTR2AL3MBTL1MAOBSMN1; SMN2MAPT | |
| SCHEMBL5719239 | 0.90 | HTR2A (0.40) | HTR2AL3MBTL1MAOBSMN1; SMN2MAPT | |
| SCHEMBL5719669 | 0.88 | LMNA (0.37) | L3MBTL1MAOBSMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL5719876 | 0.87 | LMNA (0.45) | HTR2AL3MBTL1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL5719246 | 0.87 | L3MBTL1 (0.45) | HTR2AL3MBTL1MAOBSMN1; SMN2MAPT | |
| SCHEMBL5775319 | 0.86 | GAA (0.48) | L3MBTL1ALDH1A1TSHRMAPK1 | |
| SCHEMBL5719352 | 0.86 | HTR2A (0.45) | HTR2AL3MBTL1MAOBSMN1; SMN2MAPT | |
| SCHEMBL5718930 | 0.85 | ALDH1A1 (0.47) | HTR2AL3MBTL1MAOBSMN1; SMN2MAPT | |
| SCHEMBL5719569 | 0.84 | L3MBTL1 (0.42) | HTR2AL3MBTL1MAOBSMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7074798-B2 | Xanthine derivative and DPPIV inhibitor | EISAI CO., LTD (JP) | 2006-07-11 | — | — | US | disclosed |
| US-20060094722-A1 | Combination drug | EISAI CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1338595-B1 | Xanthine derivatives as DPP-IV inhibitors | EISAI CO LTD (JP) | 2006-05-03 | — | — | EP | disclosed |
| EP-1557165-A1 | COMBINATION DRUG | Eisai Co., Ltd. (JP) | 2005-07-27 | — | — | EP | disclosed |
| US-20040082570-A1 | Xanthine derivative and DPPIV inhibitor | EISAI CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1338595-A2 | Xanthine derivatives as DPP-IV inhibitors | Eisai Co., Ltd. (JP) | 2003-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082570-A1 | Xanthine derivative and DPPIV inhibitor | DPP4, DPP9, DPP7 | HTR2A 1359/4885L3MBTL1 1200/4885MAOB 996/4885 |
| US-20060094722-A1 | Combination drug | DPP4, GLP1R, DPP7 | HTR2A 1018/4885L3MBTL1 4196/4885MAOB 4207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.